National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Erenumab (Aimovig®)  is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig®.

NCPE Assessment Process Ongoing
Rapid review received 19/07/2018
Rapid review completed 15/08/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/08/2018
Pre-submission consultation with Applicant 24/09/2018
Submission received from Applicant 22/01/2019
Preliminary review sent to Applicant 01/04/2019
NCPE assessment re-commenced 01/05/2019
Factual accuracy sent to Applicant 31/07/2019
NCPE assessment re-commenced 06/08/2019
Current status  NCPE assessment ongoing